| David T Shook, MD | |
|
2000 E Greenville St, Suite 3700, Anderson, SC 29621-1580 | |
| (864) 512-1475 | |
| (864) 512-1390 |
| Full Name | David T Shook |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 2000 E Greenville St, Anderson, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811284649 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | LL33753 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health Of Lexington | Lexington, SC | Home health agency |
| Tri County Home Health | Irmo, SC | Home health agency |
| Prisma Health Tuomey | Sumter, SC | Home health agency |
| Hospice Care Of Tri County | Columbia, SC | Hospice |
| Amedisys Hospice Of South Carolina | Florence, SC | Hospice |
| Caris Healthcare, Greenville | Greenville, SC | Hospice |
| Prisma Heath Tuomey Hospital | Sumter, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolina Geriatric Specialists, Llc | 2163693532 | 4 |
News Archive
Researchers at the University of Maryland and Duke University have designed a novel protein-sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV. The molecule could one day become part of a successful HIV vaccine.
"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Neuronal Ceroid Liposfuscinosis (NCL), often referred to as Batten disease, is a rare and fatal neurodegenerative disorder that afflicts infants and young children. NCL is caused by a deficiency of a lysosomal enzyme, and is a relatively rare disease, affecting an estimated 2 to 4 of every 100,000 babies born in the U.S. Although NCLs are classified as rare diseases, they often affect more than one child in families that carry the defective gene, and tragically, are always fatal.
› Verified 7 days ago
| Entity Name | Prisma Health University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295763217 PECOS PAC ID: 8325950983 Enrollment ID: O20031103000238 |
News Archive
Researchers at the University of Maryland and Duke University have designed a novel protein-sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV. The molecule could one day become part of a successful HIV vaccine.
"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Neuronal Ceroid Liposfuscinosis (NCL), often referred to as Batten disease, is a rare and fatal neurodegenerative disorder that afflicts infants and young children. NCL is caused by a deficiency of a lysosomal enzyme, and is a relatively rare disease, affecting an estimated 2 to 4 of every 100,000 babies born in the U.S. Although NCLs are classified as rare diseases, they often affect more than one child in families that carry the defective gene, and tragically, are always fatal.
› Verified 7 days ago
| Entity Name | Carolina Geriatric Specialists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124313101 PECOS PAC ID: 2163693532 Enrollment ID: O20110914000630 |
News Archive
Researchers at the University of Maryland and Duke University have designed a novel protein-sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV. The molecule could one day become part of a successful HIV vaccine.
"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Neuronal Ceroid Liposfuscinosis (NCL), often referred to as Batten disease, is a rare and fatal neurodegenerative disorder that afflicts infants and young children. NCL is caused by a deficiency of a lysosomal enzyme, and is a relatively rare disease, affecting an estimated 2 to 4 of every 100,000 babies born in the U.S. Although NCLs are classified as rare diseases, they often affect more than one child in families that carry the defective gene, and tragically, are always fatal.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David T Shook, MD 1 Independence Pointe, Suite 212, Greenville, SC 29615-4536 Ph: (864) 797-6174 | David T Shook, MD 2000 E Greenville St, Suite 3700, Anderson, SC 29621-1580 Ph: (864) 512-1475 |
News Archive
Researchers at the University of Maryland and Duke University have designed a novel protein-sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV. The molecule could one day become part of a successful HIV vaccine.
"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Neuronal Ceroid Liposfuscinosis (NCL), often referred to as Batten disease, is a rare and fatal neurodegenerative disorder that afflicts infants and young children. NCL is caused by a deficiency of a lysosomal enzyme, and is a relatively rare disease, affecting an estimated 2 to 4 of every 100,000 babies born in the U.S. Although NCLs are classified as rare diseases, they often affect more than one child in families that carry the defective gene, and tragically, are always fatal.
› Verified 7 days ago
Justin M Moore, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4120 Highway 24, Anderson, SC 29626 Phone: 864-512-5830 Fax: 864-224-4999 | |
Mr. Wajdi Ali Dbouk, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3424 Clemson Blvd, Anderson, SC 29621 Phone: 864-261-4350 Fax: 864-261-4097 | |
Hunter E Woodall, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Suite 3700, Anderson, SC 29621 Phone: 864-512-1475 Fax: 864-512-1930 | |
Clifton Wade Straughn, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 105 Buford Ave, Anderson, SC 29621 Phone: 864-512-5901 Fax: 864-225-1058 | |
David Finney, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Suite 3700, Anderson, SC 29621 Phone: 228-424-7973 | |
Christine Lawrence, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 4144 Clemson Blvd, Anderson, SC 29621 Phone: 864-224-3332 | |
Melody S Franks, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4120 Highway 24, Anderson, SC 29626 Phone: 864-512-5830 Fax: 864-224-4999 |